MECOM在人类癌症中预后价值的系统性泛癌分析。
Systematic pan-cancer analysis of the prognostic value of MECOM in human cancer.
作者信息
Lu Yingqiang, Quan Jing, Liu Feng, Huang Banggao
机构信息
Department of Urology, Urology and Nephrology Center, Cancer Center, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, 158 Shangtang Road, Hangzhou, 310014, Zhejiang, China.
出版信息
Discov Oncol. 2024 Nov 22;15(1):694. doi: 10.1007/s12672-024-01599-5.
Recently, emerging evidence suggests an association between MECOM (MDS1 and EVI1 complex locus) and cancers. However, a comprehensive pan-cancer analysis to fully investigate this relationship is lacking. Herein, public platforms with large-scale genomics, including The Cancer Genome Atlas, Gene Expression Omnibus dataset, and the Human Protein Atlas were explored to investigate the prognostic and immunological roles of MECOM across certain cancer types. Our findings revealed differential expression of MECOM in various cancer types, indicating its potential to predict diverse clinical outcomes, such as overall survival time and disease-free survival time in patients with various malignancies. Additionally, we observed an association between the mutation burden in MECOM in various cancers and patient survival. Furthermore, the mechanism of MECOM-mediated oncogenesis was tentatively explored by immune infiltration analysis. This study provided a relatively comprehensive overview of the prognostic and immunological roles of MECOM in multiple cancers.
最近，新出现的证据表明MECOM（MDS1和EVI1复合位点）与癌症之间存在关联。然而，目前缺乏全面的泛癌分析来充分研究这种关系。在此，我们利用包括癌症基因组图谱、基因表达综合数据库和人类蛋白质图谱在内的大规模基因组学公共平台，探讨MECOM在某些癌症类型中的预后和免疫作用。我们的研究结果揭示了MECOM在各种癌症类型中的差异表达，表明其具有预测不同临床结局的潜力，例如各种恶性肿瘤患者的总生存时间和无病生存时间。此外，我们观察到各种癌症中MECOM的突变负担与患者生存之间存在关联。此外，通过免疫浸润分析初步探索了MECOM介导肿瘤发生的机制。本研究对MECOM在多种癌症中的预后和免疫作用提供了较为全面的概述。
Zotero 插件